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Two inactivated canine distemper vi us (CD tl) vaccines--an adjuvanted whole inactivated virus 
and a subunit ISCOM preparation--were t sted for their ability to indl~ce protective immunity in 
harbour seals (Phoca vitulina) against phocid distemper, a disease that recently killed > 17 000 
harbour seals in the North and Baltic seas, and was shown to be caused by infection with a newly 
discovered morbillivirus, which is antigenically closely related to CDV. Four CDV seronegative 
harbour seals were vaccinated three times with the whole-virus vaccine, two with the ISCOM 
subunit vaccine and two were sham-vaccinated with an antigen-free preparation. Ten days after 
the last vaccination, when all six vaccinated animals had developed CD V neutralizing antibody 
titres ranging from 300 to 3000, all eight animals were challenged by the oculonasal and the 
peritoneal routes, with an organ suspension from dead seals. None of the six vaccinated animals 
developed clinical signs. The two sham-vaccinated seals died on days 14 and 18, respectively, after 
having shown a body temperature rise, respiratory symptoms and weight loss. In organs from both 
dead animals morbillivirus antigen was demonstrated with an enzyme-linked immunosorbent assay 
and an immanofluorescence assay. One of th se two animals had developed a low titre of 
CD V-specific antibodies ju t before death. These data clearly indicate hat seals can be protected 
from fatal challenge with the phocid distemper virus ( PD V) , by vaccination with certain inactivated 
CDV vaccines. They also reconfirm that infection with PDV should be considered theprimary 
cause of the recent epizootic in seals. 
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Introduction 
Since April 1988 > 17 000 harbour seals have died in the 
North and Baltic seas, during an outbreak of an acute 
infectious disease 1-3. The primary cause of the disease 
proved to be infection with a newly discovered morbilli- 
virus, phocid distemper virus (PDV), which was anti- 
genically closely related to canine distemper virus 
(CDV) 4-9. Apart from abortion, which was mainly 
observed at the beginning of the outbreak when most 
pups of that season were still to be born, the clinical 
signs were fairly similar to those observed in canine 
distemper4'S'9'~°: they included respiratory and gastro- 
intestinal symptoms, neurological signs, cutaneous lesions, 
general depression and also a variety of secondary viral, 
bacterial and parasitic infections 2'4'9'~. Experimental 
infection of specified pathogen-free (SPF) dogs resulted 
in a mild form of clinical distemper, as also proved to 
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be the case when SPF dogs were infected with a fully 
virulent strain of CDV lz. 
Although preventive vaccination i wild animal species 
should generally not be recommended, there proved to 
be an urgent need for a vaccine during the outbreak in 
sanctuaries, aquaria and for certain isolated groups of 
seals of particular value 13. In the absence of a suitable 
large-scale production system for PDV and in the light 
of the close antigenic relationship with CDV, the use of 
CDV vaccines was considered for this purpose. However, 
the CDV vaccines currently used in dogs are all live 
attenuated vaccines, which are not recommended forwild 
live animals, because of the danger of insufficient 
attenuation, and spread to other wild-animal species 14. 
The use of inactivated morbillivirus vaccines has had 
little success in inducing protective immunity ~-17. 
However, we have recently shown that a subunit ISCOM 
CDV vaccine did induce protective immunity in dogs 
against challenge with a virulent CDV strain lz. Another 
inactivated vaccine, based on adjuvated whole CDV, was 
recently claimed to be effective in dogs by Duphar BV 
(personal communication, Dr M. Westrate, Duphar BV, 
Weesp, The Netherlands), which is being developed for 
commercial purposes. After having noticed that CDV- 
seronegative seals admitted to the seal sanctuary in 
Pieterburen showed better survival rates during the 
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outbreak after vaccination with either of the two vaccines, 
a CDV vaccination and challenge experiment was 
performed in CDV-seronegative s als. This experiment 
with these CDV-vaccines, in a small number of adult 
CDV-seronegative harbour seals, which belonged to a 
breeding roup in The Netherlands i described. These 
animals had remained free of PDV infection and the 
clinical symptoms observed uring the recent outbreak. 
A selection of preliminary data obtained in these 
experiments has recently been published la, in order to 
inform sanctuaries and the nature management organiza- 
tions about he possibilities of vaccination. Both vaccines 
tested proved to induce CDV neutralizing antibodies and
protection against fatal PDV challenge. 
Materials and methods 
Seals 
Experimental vaccination with CDV vaccine prepar- 
ations was carried out in two different groups of harbour 
seals. The first was the group of harbour seals admitted, 
during the outbreak, to the seal sanctuary of the Seal 
Rehabilitation and Research Centre at Pieterburen (The 
Netherlands), where mainly baby seals are routinely 
nursed until they can be reintroduced to the wild. The 
second was a breeding roup of about 40 harbour seals 
which had been kept in isolation for many years at the 
island of Texel in the Dutch Wadden sea. In this group 
no PDV infection had occurred so far, as was shown by 
the absence of CDV-specific antibodies in the sera of 
these seals and by the absence of clinical symptoms. Eight 
adult seals of this group were used for challenge with 
PDV after the vaccination- or sham-vaccination series 
had been completed. 
CD V vaccines 
Two different candidate CDV vaccines were used. The 
first was the candidate subunit CDV-ISCOM vaccine 
prepared from the Rockborn strain of CDV in collabor- 
ation with Coopers Animal Health Ltd (Berkhamsted, 
UK), as previously described, which predominantly 
contained the F protein of the virus 12. The second was 
an inactivated and adjuvanted whole CDV preparation 
based on the Onderstepoort s rain of CDV, kindly 
provided by Duphar BV (Weesp, The Netherlands), 
which is being developed for commercial use. 
PD V challenge preparation 
Challenge material consisted of a 0.5 % (v/v) suspension 
of a pool of spleen, lung and intestinal lymph-node cells 
taken from three harbour seals, which had died from the 
disease during the outbreak in the Dutch Wadden sea 
area. This preparation had been shown to induce 
distemper-like clinical symptoms, CDV-neutralizing 
antibody titres and viraemia in SPF dogs, after intra- 
peritoneal and oculonasal inoculation with a 10% 
suspension of the same inoculum 5.
Protection studies 
From 15 August 1988 an experimental CDV vaccination 
regimen was introduced for the seals admitted to the seal 
sanctuary in Pieterburen. All seals lacking CDV- 
neutralizing antibodies at admission were vaccinated 
three times at intervals of 7-14 days, either with the 
ISCOM preparation or with the inactivated whole-virus 
candidate vaccine. Survival rates during the outbreak in 
this sanctuary were recorded. 
In the challenge xperiment eight CDV-seronegative 
adult harbour seals were used, of which two were 
vaccinated with the CDV-ISCOM vaccine, four with the 
inactivated adjuvanted whole-virus CDV-vaccine and 
two with an antigen-free preparation. The animals were 
vaccinated three times intramuscularly. The first two 
vaccinations were carried out on days -59 and -42, 
followed by a final vaccination on day -10. Blood 
samples were collected before starting the experiment, 14 
days after the first two vaccinations and on the day of 
challenge (day 0). Ten days after the last vaccination, all 
eight animals were transferred toa closed swimming pool, 
where they were challenged via the oculonasal and 
peritoneal routes with 2ml of the PDV challenge 
material. After challenge, clinical signs were recorded and 
necropsy was performed on animals that died. Body 
temperatures and weights were determined on days 0, 4, 
5, 6, 7, 11, 14 and 21 after challenge, when blood samples 
were also collected for serological studies. 
Serological tests 
Serum samples collected from seals in the sanctuary 
and from the eight animals in the challenge xperiment 
were examined for their levels ofCDV-specific antibodies 
by a CDV antibody ELISA (CDV-ELISA), a CDV 
neutralization assay (CDV-VN) and in a Western blot 
assay. 
CD V ELISA. ELISA was carried out essentially as 
described for the detection of measles virus specific 
antibodies 12. In short, CDV (Bussel strain 19) -infected 
Vero cells, showing complete cytopathologic effect (cpe), 
were lysed by freeze-thawing and after low-speed centri- 
fugation the resulting suspension was used for overnight 
coating (RT) in carbonate buffer (pH 9.6). A non-infected 
Vero cell preparation treated in the same way served as 
a control antigen. HRPO-labelled rabbit-anti-seal serum, 
raised against protein-A purified seal immunoglobulins 
was used as second antibody. ELISA titres were deter- 
mined by measuring the s rum dilutions till giving 50% 
of the maximum substrate reaction and expressed as the 
reciprocal of these dilutions. 
CD V-VN. Neutralization assays were carried out as 
described previously, using the Bussel strain of CDV, 
Vero cells and serial threefold serum dilutions 12. VN 
titres were expressed as the reciprocal of the serum 
dilutions till giving complete reduction of cpe, using 100 
TCIDso. 
Western blot assay. The protein specificities of serum 
antibodies raised upon immunization with the different 
vaccines and upon challenge were examined by Western 
blot analysis essentially as described by Towbin et 
a/. 2°-23. The proteins of sucrose gradient (30-60% 
sucrose in TN buffer)-purified CDV (Rockborn strain) 
were separated on a 12.5% SDS-polyacrylamide g l24, 
after which they were electrophoretically transferred to 
nitrocellulose sheets (0.2#m Schleicher and Schuell). 
T O preparg the sheets for imm;:nostaining, additional 
protein-binding capacity was blocked by a 1 h incubation 
at 37°C with blot buffer (PBS supplemented with 0.05% 
(v/v) Tween 80, 1% (w/v) BSA, 5% (v/v) SPF rabbit 
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Figure 1 Percentages of seals surviving in the Seal Sanctuary 
Pieterburen from April to December 1988. Number of seals admitted 
monthly are shown above each column: [~, with CDV-neutralizing serum 
antibodies (titre />20); m, without CDV-neutralizing serum antibodies. 
From 15 August (arrow) seals that were admitted without CDV- 
neutralizing serum antibodies were vaccinated with either of the 
two candidate CDV-vaccines 
serum and 5% NaC1). Serum samples taken at different 
times during the experiment were diluted 1:50 in blot 
buffer and incubated for 1.5 h on nitrocellulose strips. 
The strips were washed twice with tap water and 
subsequently twice for 5 min with PBS containing 0.05% 
Tween 80 (PBS-T). Strips were then incubated for 1 h at 
20°C with an HRPO-labelled rabbit-anti-seal preparation 
diluted in blot buffer, washed again with tap water and 
PBS-T and stained using TMB/DONS as described 25. 
Antigen demonstration 
Morbillivirus antigen present in organ material taken 
from the two sham-vaccinated seals after capture was 
detected by an antigen-detection ELISA and/or an 
immunofluorescence assay (IFA). 
Antigen-capture ELISA. An antigen-capture ELISA 
was used to detect PDV antigen in 10% (v/v) suspensions 
of lung, brain, spleen, kidney and liver samples, 
essentially as previously described 26. The F-specific 
monoclonal antibody A 1074 (clone 5006), kindly 
provided by Dr C. Orvell z7, was used as a coating to 
the microtitre plate (Costar EIA/RIA Strip plate-8) 
(overnight, 20°C), on which the different organ suspen- 
sions were incubated overnight at 4°C. After incubation 
for 1 h at 37°C with polyclonal hyperimmune anti-CDV 
dog serum followed by incubation for 1 h at 37°C 
with HRPO-labelled goat-anti-dog-IgG/IgM (Cappel), 
staining was provided using TMB as a substrate 
as described 'z. 
Immunofluorescence assay. Immunofluorescence analy- 
sis of CDV-like antigen was carried out on cryostat 
sections of different organs, using the anti-F monoclonal 
antibody A 1074 (C. Orvell) and an anti-mouse FITC 
conjugate (Dakopatts), as described previously 28. 
Post-mortem investigation 
Gross necropsy was performed on the two sham- 
vaccinated seals that had died. Several tissues were 
sampled for additional histopathological examination. 
After fixation in Bouin's fixative or in a phosphate- 
buffered neutral 4% formaldehyde solution, 4pm para- 
plast-embedded tissue sections were stained with haema- 
toxylin and eosin and examined under the light 
microscope. 
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Results 
Antibody development and survival of seals 
in the Seal Sanctuary, Pieterburen 
From 15 August 1988 all seals admitted to the Seal 
sanctuary in Pieterburen that had no CDV-VN serum 
antibody titre upon admission (titre < 10) were vaccinated 
three times, either with the candidate CDV ISCOM or 
with the candidate inactivated whole CDV vaccine. 
CDV-VN antibody titres in surviving seals, measured 
>2 months after admission, ranged from 30 to 3000 
(2=810) in the vaccinated animals and from 100 to 300 
(2 = 270) in those non-vaccinated animals with CDV-VN 
serum antibodies on admission. No clear differences in 
survival rates or antibody development were observed 
between the groups of animals vaccinated with either of 
the two vaccines. Vaccination of the seals with these 
vaccines appeared to induce protection, as it resulted in 
a dramatic decrease in the mortality rates compared with 
the non-vaccinated group: survival percentages increased 
from <10% to >60% within 1 month, whereas they 
remained < 30% in the non-vaccinated animals (Figure 
I). 
Antibody development and survival of seals 
in the experimental group 
The development of CDV-VN serum antibodies upon 
vaccination was recorded in the experimental group. The 
two seals vaccinated with the ISCOM preparation and 
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Figure 2 (a) Development of CDV-VN serum antibody titres and (b) 
CDV-ELISA serum antibody titres in the experimental group of seals 
after three vaccinations on day --59, --42 and --10 (dark arrows),, as 
measured on day --42, day -- 10 and day 0 (day of challenge) and upon 
challenge (open arrow) as measured on days 4, 5, 7, 11, 14 and 21 after 
challenge: m, ISCOM-CDV vaccinated seals; FI, inactivated whole CDV 
vaccinated seals 
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Figure 3 Western blot analysis of serum samples taken before vaccination (pre), after vaccination (day 0) and after challenge (No. 2701-No. 2706: 
day 21; No. 2707 and No. 2708; day 14 and 18 respectively) from eight seals involved in the challenge experiment hat were vaccinated with the 
ISCOM-CDV vaccine (No. 2701 and No. 2702), with the inactivated whole CDV vaccine (i.a. CDV) (No. 2703, No. 2704, No. 2705 and No. 2708), or with 
the antigen-free preparation (sham) (No. 2707 and No. 2708) 
Table 1 Clinical signs upon challenge observed in two sham-vaccinated seals 
Body temperature Nasal discharge Neurological 
> 1°C above and/or respiratory symptoms on 
normal on day: distress on day: day: 
Weight loss 
Seal no. (kg on day 14) 0 7 11 14 18 0 7 11 14 18 0 7 11 14 17 18 
2707 5.1 - - - t - - + I" - - - 1. 
2708 11.4 -- - + + 1" - - - + I . . . .  + 1" 
+,  Presence of elevated body temperature, signs of respiratory distress or neurological signs as indicated; 1", dead 
the four vaccinated with the inactivated vaccine all 
developed titres gradually increasing from 10 to 1000 
during the vaccination procedure. During the period 
following challenge, the titres further increased in both 
groups to levels between 1000 and 10 000 (Figure 2a). A 
similar pattern of antibody development was observed 
when the sera were tested in the CDV-ELISA (Figure 
2b). Of the sham-vaccinated seals, one developed CDV- 
specific serum antibodies upon challenge as detected in 
CDV-VN (titre 30) and in CDV-ELISA (titre 100), 
whereas the other emained seronegative to CDV in both 
assays. However, the development, upon challenge, of 
PDV-specific antibodies, not cross-reacting with CDV, 
cannot be ruled out on the basis of these data. 
Development of serum antibodies, after vaccination 
and challenge, to the respective structural CDV proteins 
was monitored in all these animals by Western blot 
analysis. Although the CDV-ISCOM preparation pre- 
dominantly contained the F protein, antibodies to other 
viral proteins were also induced upon vaccination, as had 
also been oticed in experiments in dogs 12. In one of the 
two ISCOM-vaccinated seals (No. 2701), a pronounced 
antibody development to the NP and F proteins was 
observed after vaccination, which did not change 
significantly upon challenge. The other ISCOM- 
vaccinated seal (No. 2702) developed antibodies to these 
and also to the H and M proteins, which response also 
did not change significantly upon challenge (Figure 3). 
The seals vaccinated with the inactivated vaccine 
predominantly developed antibodies to the NP and F 
proteins, which responses also did not alter upon 
challenge. No antibody development could be detected 
by Western blot analysis against CDV proteins in 
the sham-vaccinated animals upon vaccination and 
challenge. 
Upon challenge, the six vaccinated seals survived for 
at least the whole experimental period (5 months) 
whereas the sham-vaccinated seals died on days 14 and 
18 respectively. 
Clinical signs and post-mortem findings 
in the experimental group 
All six vaccinated seals remained free of clinical signs 
indicative of phocid distemper. The two sham-vaccinated 
seals, however, developed symptoms of distemper includ- 
ing respiratory distress, mucopurulent asal discharge, 
elevated body temperature and weight loss after challenge. 
These symptoms were similar to those observed in and 
outside the seal sanctuary during the distemper out- 
break 2'4's'9'29. One of them (No. 2708) also developed 
convulsive seizures, which, together with other neuro- 
logical symptoms, are regularly observed in animals with 
phocid distemper 11'29 (Table I). They died on days 14 
and 18, respectively. 
Investigation of organ suspensions ofboth dead seals 
(No. 2707 and No. 2708) for the presence of morbillivirus 
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Rgure 4 Eosinophilic cytoplasmic inclusion body in a bronchial 
epithelial cell (arrow). Desquamative and purulent exudate is present 
in the lumen (A). (HE 800 x) 
antigen in the antigen-ELISA, yielded a positive result 
with the spleen suspension of seal No. 2707 and with the 
lung suspension of seal No. 2708. In the latter, 
morbillivirus antigen was also demonstrated byindirect 
IFA on cryostat sections of the lungs. 
Gross necropsy of the sham-vaccinated animals 
revealed signs compatible with the clinical findings, i.e. 
mucopurulent asopharyngitis, notably in No. 2708, and 
severe emaciation with atrophy of the subcutaneous 
adipose layer and a decreased volume of the intestinal 
tract. Haemochromatosis, mainly hepatic, was seen in 
both animals. Seal No. 2707 was suffering from a 
membranous glomerulopathy. The most striking histo- 
pathological finding consisted of cytoplasmic nclusion 
bodies, which were found in bronchial epithelium and in 
the renal pelvic urothelium of one animal (Figure 4). 
They were rounded and sharply delineated, eosinophilic 
and sometimes multiple. 
Discussion 
Recent evidence, mainly consisting of virus isolation and 
serological data, has shown that the primary cause of the 
recent epizootic among seals in north-western Europe 
was infection with a morbillivirus (PDV) closely related 
to, but probably distinct from, CDV 2'4-9'11,18. For final 
proof of the aetiological role of PDV, a challenge 
experiment in seals, which either had, or had not 
previously been exposed to or vaccinated against PDV 
was necessary s'ls. In the present paper we have shown, 
that harbour seals could, indeed, be protected against 
phocid distemper with certain inactivated CDV vaccines, 
confirming the close antigenic relationship between these 
two morbilliviruses. This had already been indicated 
by results of cross-VN, ELISA, IFA and nucleic acid 
hybridization studies 5-s' 16. Indications that these vaccines 
induced protection had already been obtained at the Seal 
Sanctuary, Pieterburen, by demonstration of a clear 
difference between survival of vaccinated versus non- 
vaccinated seals. Although it can be argued that the 
non-vaccinated animals were already infected with 
PDV before admission, it could be concluded from the 
data, presented in Figure 1, that PDV did spread rapidly 
through the sanctuary, implying that the vaccinated seals 
must also have been exposed to PDV-infection during 
their stay in the sanctuary. The symptoms observed in 
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the two sham-vaccinated seals, which died in the 
experimental group after challenge with material that had 
been shown to contain infectious PDV in a previous 
experiment in SPF dogs 5, included weight loss, fever, 
respiratory disease and neurological symptoms. These 
were symptoms which have also been observed in animals 
suffering from the disease in and outside the sanc- 
tuary 2'4'9'11'26 In the six vaccinated animals, such 
symptoms were not recorded. Viral antigen was detected 
in tissues of the sham-vaccinated s als after death and, in 
one of them, cytoplasmic nclusion bodies were found in 
lung and kidney. The presence of morbillivirus RNA was 
demonstrated in the spleens of both animals (T. Barrett, 
Institute for Animal Health, Pirbright, UK, unpublished 
observations). The serum antibody responses to PDV, 
as measured on the basis of their cross-reactivity to CDV 
in CDV-VN, CDV-ELISA and Western blot, in these 
vaccinated seals indicated that all these animals had 
developed high levels of serum antibodies to CDV and 
PDV, and probably protective immunity against the 
latter, which was a prerequisite for performing the 
challenge infection. Although after, the challenge a slight 
increase in serum antibody titres in the CDV-VN and 
CDV-ELISA was observed (which was not, however, 
demonstrable in the Western blot analysis), it cannot be 
concluded from these data that PDV replicated in the 
vaccinated animals after challenge, because this increase 
could also be attributed to the vaccination procedure 
itself. The absence of CDV-VN and CDV-ELISA 
antibodies in one of the sham-vaccinated s als and the 
absence of antibodies reactive with CDV proteins in 
Western blot analysis in both upon challenge with PDV, 
may perhaps be attributable in part to antigenic 
differences between CDV and PDV. The animals could, 
in the short period after challenge, have developed 
low-titred PDV-specific antibodies, not detectable in 
the heterologous assays. In principle, the successful 
results obtained in this vaccination experiment indicates, 
(although only a limited number of seals were included) 
that seals can, indeed, be protected by vaccination with 
inactivated CDV vaccines against phocid distemper. For 
several reasons, vaccination will be limited to seals kept 
in captivity in sanctuaries and zoos. Apart from the 
fundamental question of whether vaccination of wild 
animals hould be considered at all, it is not only difficult 
and stressful to capture animals in the wild, but also a 
multiple-dose r gimen would not be practical 13. Further 
studies to evaluate the duration of immunity, the 
possibility of reduction of the number of subsequent 
vaccinations and, perhaps, the eventual change from 
vaccination with CDV vaccines to a genuine inactivated 
PDV vaccine, should be conducted. 
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